MERGER CONTROL IN THE BIOTECH INDUSTRY UNDER THE EU MERGER REGULATION

1. INTRODUCTION

Merger Control in the Biotechnology Industry under the European Union Merger Regulation (EUMR) concerns the legal supervision of mergers, acquisitions, joint ventures and corporate consolidations involving biotechnology, pharmaceutical, genetic engineering, medical diagnostics and life-sciences companies.

The principal legislation is Council Regulation (EC) No. 139/2004 on the Control of Concentrations Between Undertakings, commonly known as the EU Merger Regulation.

Biotechnology mergers can significantly affect competition because companies may control essential patents, genetic sequencing technologies, research pipelines, clinical trial platforms, biological manufacturing facilities and innovative medicines. Acquisitions of smaller biotechnology companies may also eliminate potential competitors before their products reach commercial markets.

The principal objectives of merger control are to prevent the creation or strengthening of market dominance, preserve scientific innovation, protect consumer interests and maintain competitive access to essential biotechnology technologies.

2. LEGAL FRAMEWORK UNDER THE EU MERGER REGULATION

A. ARTICLE 1 – JURISDICTION AND TURNOVER THRESHOLDS

Article 1 establishes the turnover thresholds determining whether a concentration has an EU dimension.

The principal thresholds include:

Combined worldwide turnover exceeding €5 billion and EU-wide turnover exceeding €250 million for each of at least two participating undertakings.

An alternative threshold involving worldwide turnover exceeding €2.5 billion, combined turnover exceeding €100 million in each of at least three Member States, and additional individual and EU-wide turnover requirements.

The two-thirds rule may exclude transactions where each undertaking achieves more than two-thirds of its EU-wide turnover in the same Member State.

B. ARTICLE 3 – DEFINITION OF CONCENTRATION

Article 3 covers transactions involving:

Mergers between previously independent undertakings.

Acquisition of direct or indirect control.

Creation of full-function joint ventures.

In biotechnology, acquisitions of pharmaceutical research companies, genetic diagnostic businesses and developers of innovative biological therapies may constitute concentrations.

C. ARTICLE 4 – PRIOR NOTIFICATION

Concentrations with an EU dimension must be notified to the European Commission before implementation, subject to the applicable statutory exceptions.

D. ARTICLE 6 – PRELIMINARY EXAMINATION

The Commission examines notified transactions and may approve them, approve them subject to conditions or initiate an in-depth investigation.

E. ARTICLE 8 – FINAL DECISIONS

The Commission may declare a concentration compatible with the internal market, impose appropriate conditions and obligations, or prohibit a transaction that significantly impedes effective competition.

F. ARTICLE 22 – REFERRALS

Article 22 provides a mechanism through which Member States may request the Commission to examine certain transactions that affect trade between Member States and threaten significantly to affect competition within the requesting Member State.

The interpretation of this provision was particularly important in the Illumina/GRAIL litigation.

3. SPECIAL COMPETITION CONCERNS IN THE BIOTECH INDUSTRY

A. INNOVATION COMPETITION

A biotechnology merger may eliminate a competing research pipeline even when neither company currently sells a commercial product. Regulators examine whether the acquisition could reduce future innovation.

B. PATENT AND TECHNOLOGY CONCENTRATION

Acquisitions involving genetic sequencing patents, gene-editing platforms, therapeutic technologies and proprietary biological processes may create barriers to entry for competing businesses.

C. KILLER ACQUISITIONS

A killer acquisition occurs when an established company acquires an emerging competitor, potentially to discontinue or weaken an innovative project that could otherwise challenge its market position.

D. ACCESS TO ESSENTIAL TECHNOLOGIES

Regulators examine whether a merged company could restrict competitors' access to essential research instruments, genetic databases, biological materials, manufacturing capacity or diagnostic platforms.

E. RESEARCH AND DEVELOPMENT PIPELINES

The Commission may investigate whether a merger reduces independent research programmes, clinical development alternatives or the number of companies competing to develop future treatments.

4. IMPORTANT CASE LAWS ON BIOTECHNOLOGY MERGER CONTROL

A. DIRECT BIOTECHNOLOGY AUTHORITIES

1. Illumina Inc. v. European Commission (Case T-227/21, 2022)

The General Court examined the European Commission's decision to investigate Illumina's proposed acquisition of GRAIL, a biotechnology company developing blood-based early cancer detection tests.

The dispute concerned the Commission's jurisdiction to examine a transaction referred by national competition authorities under Article 22 of the EUMR.

The General Court initially upheld the Commission's interpretation of Article 22.

Legal principle: Biotechnology acquisitions involving emerging technologies and innovation competition may attract merger scrutiny even when the target has limited turnover. However, the jurisdictional interpretation was subsequently overturned by the Court of Justice in 2024.

2. Illumina Inc. and Grail LLC v. European Commission (Joined Cases C-611/22 P and C-625/22 P, 2024)

On 3 September 2024, the Grand Chamber of the Court of Justice overturned the General Court's judgment concerning the Commission's jurisdiction under Article 22.

The Court held that a national competition authority cannot refer a transaction under Article 22 where it lacks competence to examine that transaction under its national merger-control legislation.

Legal principle: European merger-control jurisdiction must respect statutory authority, legal certainty and the limits of Article 22.

This is a particularly important biotechnology merger-control judgment because it concerned genetic sequencing technology and early cancer detection innovation.

3. Dow/DuPont Merger (Case M.7932, European Commission, 2017)

The Commission examined the proposed merger between Dow Chemical and DuPont, which involved significant agricultural biotechnology, crop protection and research activities.

The Commission identified competition concerns involving innovation, research and development capabilities and agricultural chemical markets. It granted conditional clearance subject to substantial divestment commitments.

Legal principle: Merger control must examine the effects of corporate consolidation on innovation competition and future research pipelines, rather than considering only existing product prices.

4. Bayer/Monsanto (Case M.8084, European Commission, 2018)

The Commission reviewed Bayer's acquisition of Monsanto, involving agricultural biotechnology, genetically modified seeds, crop protection products and digital farming technologies.

The transaction raised concerns about competition in seeds, traits, pesticides and innovation. The Commission approved the acquisition subject to extensive divestiture commitments, including businesses transferred to BASF.

Legal principle: Biotechnology mergers may require structural remedies, including divestment of research assets, intellectual property and commercial operations, to preserve effective competition.

B. ANALOGOUS EU MERGER-CONTROL AUTHORITIES

5. Siemens AG v. European Commission (Case T-451/20, 2023)

The General Court examined the Commission's prohibition of the proposed Siemens/Alstom railway merger.

The Court upheld the Commission's decision, rejecting the challenge to its competition assessment.

Legal principle: Merger authorities may examine future competitive conditions and market structure when evaluating whether a concentration would significantly impede effective competition.

6. CK Telecoms UK Investments Ltd v. European Commission (Case C-376/20 P, 2023)

The Court of Justice examined the Commission's prohibition of the proposed acquisition of O2 by Hutchison 3G UK.

The judgment clarified the evidentiary and legal requirements for establishing a significant impediment to effective competition under the EUMR.

Legal principle: Merger prohibition requires a sufficiently substantiated competitive assessment; speculative concerns alone are insufficient.

5. MERGER REVIEW PROCEDURE AND REGULATORY ENFORCEMENT

The European Commission generally follows two principal investigation stages.

A. PHASE I INVESTIGATION

The initial investigation normally lasts 25 working days after notification, subject to applicable procedural rules and extensions.

The Commission may:

Approve the transaction without conditions.

Approve it subject to commitments.

Initiate an in-depth Phase II investigation.

B. PHASE II INVESTIGATION

The in-depth investigation normally lasts 90 working days, subject to statutory extensions and adjustments.

The Commission may examine:

Market concentration and competitive structure.

Patent ownership and licensing arrangements.

Research and development pipelines.

Innovation incentives.

Access to biological technologies.

Potential exclusion of competing biotechnology companies.

Effects on pharmaceutical and diagnostic markets.

C. STANDSTILL OBLIGATION

Article 7 prohibits implementation of a concentration subject to the EUMR before notification and clearance, subject to specified exceptions.

In the Illumina/GRAIL matter, the Commission imposed fines in 2023 for implementation before approval. Those decisions were subsequently withdrawn following the Court of Justice's 2024 jurisdictional judgment.

D. REMEDIES AND PENALTIES

Under Article 8, the Commission may impose remedies, including:

Divestiture of biotechnology businesses.

Transfer or licensing of intellectual property.

Maintenance of independent research operations.

Access obligations concerning essential technologies.

Measures preventing discriminatory treatment of competitors.

Article 14 provides for financial penalties for specified infringements, including certain notification and implementation violations.

6. PRACTICAL COMPLIANCE REQUIREMENTS FOR BIOTECH COMPANIES

Companies planning mergers, acquisitions or joint ventures should:

Determine whether the transaction satisfies EU or national merger-notification thresholds.

Conduct competition assessments before signing and implementing transactions.

Identify overlapping patents, research pipelines and biotechnology platforms.

Evaluate potential effects on innovation and future competition.

Examine whether the transaction could eliminate an emerging competitor.

Prepare supporting economic and scientific evidence.

Obtain appropriate competition-law advice concerning referral possibilities.

Avoid premature integration before obtaining required clearance.

Develop suitable divestiture or licensing commitments where necessary.

Maintain documentary records of regulatory communications and compliance.

7. CONCLUSION

Merger Control in the Biotechnology Industry under the EU Merger Regulation is essential for maintaining competition, encouraging scientific innovation and preventing excessive concentration of biotechnology markets.

The EU Merger Regulation, particularly Articles 1, 2, 3, 4, 7, 8 and 22, establishes the principal framework for reviewing biotechnology acquisitions and corporate consolidations.

The Illumina/GRAIL litigation demonstrates the importance of jurisdiction, innovation competition and legal certainty. The Dow/DuPont and Bayer/Monsanto decisions further demonstrate that biotechnology mergers may require extensive structural remedies to protect research competition and market access.

Ultimately, effective biotechnology merger control must balance commercial investment, scientific progress, intellectual-property protection and competitive market conditions. Its purpose is to ensure that corporate consolidation does not unnecessarily eliminate innovation, restrict access to essential technologies or undermine competition within the European Union.